share_log

Chardan Capital Maintains Buy on Arbutus Biopharma, Raises Price Target to $5

Benzinga ·  Nov 20 05:58  · Ratings

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $4.5 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment